Skip to main content

Table 3 The Total Public Expenditure on OMPs in Euro per Capita in 7 EU Countries in 2013 and 2014

From: The European challenges of funding orphan medicinal products

 

Austrial

Belgium

Bulgariam

Czech Republicn

Hungary

Poland

Slovenia

2013

 Total public expenditure on OMPs in local currency

98,600,000 €a

245,000,000 €b

16,201,220 BGNc

1,100,000,000 CZKd

9,577,605,323 HUFe

212,725,536 PLNf

16,893,308 €g

 Eurostat exchange rate - annual data (/1 €)

  

1.96 BGNh

25.98 CZKh

296.87 HUFh

4.20 PLNh

 

 Total public expenditure on OMPs in €

98,600,000

245,000,000

8266,000

42,340,000

32,262,000

50,649,000

16,893,000

 Size of population

8,500,000j

11,161,642i

7,284,552i

10,516,125i

9,908,798i

38,062,535i

2,058,821i

 Total public expenditure on OMPs in €/capita

11.60

21.95

1.13

4.03

3.26

1.33

8.21

2014

 Total public expenditure on OMPs in local currency

109,800,000 €a

280,000,000 €b

23,967,183 BGNc

1,400,000,000 CZKo

12,501,994,171 HUFe

348,368,792PLNf

19,853,716 €g

 Eurostat exchange rate - annual data (/1 €)

  

1.96 BGNh

27.54 CZKh

308.71 HUFh

4.18 PLNh

 

 Total public expenditure on OMPs in €

109,800,000

280,000,000

12,228,000

50,835,000

40,496,000

83,342,000

19,854,000

 Size of population

8,500,000k

11,180,840i

7,245,677i

10,512,419i

9,877,365i

38,017,856i

i2,061,085

 Total public expenditure on OMPs in €/capita

12.92

25.04

1.69

4.84

4.10

2.19

9.63

 Average of total expenditure on OMP in €/capita in 2013 and 2014

12.26

23.50

1.41

4.43

3.68

1.76

8.92

  1. Sources: a Federation of Austrian Social Insurance Institutions (Hauptverband der österreichischen Sozialversicherungsträger)
  2. bNational Institute for Health and Disability Insurance of Belgium (Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor ziekte-en invaliditeitsverzekering, INAMI / RIZIV)
  3. cNational Health Insurance Fund of Bulgaria, National Council on Prices and Reimbursement of Medicinal Products
  4. dState Institute for Drug Control (Státní ústav pro kontrolu léčiv, SUKL)
  5. e National Health Insurance Fund Administration of Hungary (Országos Egészségbiztosítási Pénztár, OEP)
  6. fNational Health Fund (Narodowy Fundusz Zdrowia), Ministry of Health (Ministerstwo Zdrowia)
  7. g Health Insurance Institute of Slovenia (Zavod za zdravstveno zavarovanje Slovenije, ZZZS)
  8. h http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=ert_bil_eur_a&lang=en
  9. ihttp://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_gind&lang=en
  10. jAustrian data was not available on Eurostat database, the source: https://data.oecd.org/pop/population.htm
  11. kAustrian data was not available on Eurostat or OECD database, the calculated number was taken from the previous year
  12. lOrphan drug expenditure in hospitals not included
  13. mThese data was based on 10 OMs reimbursed by National Health Insurance Fund
  14. nAdditional drugs were identified which held orphan designation until 2013/14 with significant costs (Glivec, Ilaris, Ventavis)
  15. oData was not available at time of data request; this number assumes same total expenditure on public healthcare as in year 2013